Is the Delphi's Oracle Pertinent to Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma?-Reply

JAMA Oncol. 2022 Dec 1;8(12):1851-1852. doi: 10.1001/jamaoncol.2022.4676.

Authors

J Annelie Suurmeijer^{1

2}, Marc G Besselink^{1

2}, Hanneke W M van Laarhoven^{2

3}

Affiliations

¹ Department of Surgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
² Cancer Center Amsterdam, Amsterdam, the Netherlands.
³ Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.

PMID: 36201220
DOI: 10.1001/jamaoncol.2022.4676

No abstract available

Publication types

Letter
Comment

MeSH terms

Adenocarcinoma*
Carcinoma, Pancreatic Ductal* / pathology
Carcinoma, Pancreatic Ductal* / surgery
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms* / pathology
Pancreatic Neoplasms* / surgery